Analysis of the structure and dynamics of epidemiological indicators of renal cell carcinoma in the world and Ukraine

Authors

DOI:

https://doi.org/10.24959/sphhcj.24.329

Keywords:

renal cell carcinoma; prevalence; incidence; epidemiological profile of the population

Abstract

Aim. To analyze the structure and dynamics of epidemiological indicators of renal cell carcinoma (RCC) worldwide and in Ukraine.

Materials and methods. The study materials were publications in scientific journals, statistical reports of international and national health organizations, including data from the Global Cancer Observatory (GLOBOCAN) and European Association of Urology databases, as well as data from the Ukrainian National Cancer Registry Bulletin and official statistics from various regions of Ukraine. The methods of content analysis, comparative, logical, analytical, mathematical, graphical methods, and generalization of information were used in the study.

Results. According to the results of the analysis, it has been found that the incidence of RCC varies considerably around the world, with the highest rates in North America, Eastern and Northern Europe and the lowest in Africa and South Asia. In the United States, about 79,000 new cases of RCC are registered annually, while in Europe, 145,000 cases were reported in 2022. In Ukraine, 3,544 people fell ill with RCC in 2022, of whom 1,238 died. The highest number of cases of RCC was observed in men (2126 cases versus 1418 among women). Among the new cases of RCC in 2022, 20.3 % of patients did not live more than one year. It has been determined that there is heterogeneity in the incidence of RCC in different regions of Ukraine. Thus, the largest number of reported cases of RCC (absolute value) in 2022 was observed in Dnipro (344 cases), Lviv (313 cases) regions and the city of Kyiv (234 cases). The lowest number of new cases of renal malignancies was recorded in the temporarily occupied areas from the active hostilities zone (Luhansk, Donetsk, Kherson regions), as well as in Mykolaiv (39 cases) and Chernivtsi (68 cases) regions. The regional differences identified in the morbidity and mortality of patients with RCC may be due to various factors, including, first of all, epidemiological, socio-demographic, and medical factors.

Conclusions. It has been determined that RCC occupies a significant position in the structure of morbidity and mortality among different age and gender groups of the population both in Ukraine and in the world. In general, there is an increase in the number of cases of RCC among both men and women in the world with a significant predominance among men. It has been found that the dynamics of morbidity in Ukraine has a heterogeneous trend with an increase in the number of cases in 2019 compared to 2018; at the same time, a significant decrease in 2020 and 2022 compared to previous years. The study of the data on epidemiological indicators of RCC will further expand the possibilities for evaluating medical technologies and, accordingly, forming directions for improving existing approaches to pharmacotherapy for this group of patients in Ukraine.

References

Rak v Ukraini, 2022-2023. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten natsionalnoho kantser–reiestru Ukrainy. 2024. No. 22. Available at: http://www.ncru.inf.ua/publications/BULL_25/index.htm.

Rak v Ukraini, 2018-2019. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten natsionalnoho kantser–reiestru Ukrainy. 2021. No. 21. Available at: http://www.ncru.inf.ua/publications/BULL_21/index.htm.

Fitzmaurice, C., Dicker, D., Pain, A., Hamavid, H., Moradi-Lakeh, M., MacIntyre, M. F. et al. (2015). The global burden of cancer 2013. JAMA Oncol, 1 (4), 505-527. doi: 10.1001/jamaoncol.2015.0735.

Vitruk, Yu. V. (2019). Suchasne likuvannia nyrkovoklitynnoho raku. Zdorovia Ukrainy. Onkolohiia. Hematolohiia. Khimioterapiia, 3 (59), 29.

Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., Ulbright, T. M. (2016). The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs. Part A: Renal, Penile, and Testicular Tumours. Eur. Urol, 70 (1), 93-105. doi: 10.1016/j.eururo.2016.02.029.

Moch, H., Humphrey, P. A., Ulbright, T. M., Reuter, V. E. (Ed.). (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours. (4th ed.). Lyon.

Rak nyrky. Klinichna nastanova zasnovana na dokazakh / MOZ Ukrainy. 2022. 94 p. Available at: https://www.dec.gov.ua/wp-content/uploads/2022/06/2022_04_12-kn-rak-nyrky-2.pdf.

Shparyk, Ya. V. (2008). Rak nyrky: ostanni dosiahnennia medykamentoznoho likuvannia. Onkolohiia, 10 (4), 436-442.

Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J. et al. (2019). Epidemiology of Renal Cell Carcinoma. Eur Urol, 75 (1), 74-84. doi: 10.1016/j.eururo.2018.08.036.

Tahbaz, R., Schmid, M., Merseburger, A. S. (2018). Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol, 28 (1), 62-79. doi: 10.1097/MOU.0000000000000454.

Al-Bayati, O., Hasan, A., Pruthi, D., Kaushik, D., Liss, M. A. (2019). Systematic review of modifiable risk factors for kidney cancer. Urol Oncol, 37 (6), 359-371. doi: 10.1016/j.urolonc.2018.12.008.

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, Ph. D., Hawkins, R., Nosov, Ph. D. et al. (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N. Engl. J. Med, 380 (12), 1116-1127. doi: 10.1056/NEJMoa1816714.

Escudier, B., Staehler, M. (2018). New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far? Eur. Urol, 73 (1), 1-3. doi: 10.1016/j.eururo.2017.08.020.

Lam, J. S., Shvarts, O., Leppert, J. T., Pantuck, A. J., Figlin, R. A., Belldegrun, A. S. (2005). Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J. Urol, 174 (2), 466-472. doi: 10.1097/01.ju.0000165572.38887.da.

Pantuck, A. J., Zisman, A., Belldegrun, A. S. (2001). The changing natural history of renal cell carcinoma. J. Urol, 166 (5), 1611-1623.

Sun, M., Thuret, R., Abdollah, F., Lughezzani, G., Schmitges, J., Tian, Z. et al. (2011). Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol, 59 (1), 135-141. doi: 10.1016/j.eururo.2010.10.029.

Patel, D. N., Figlin, R. A., Kim, H. L. (2016). Adjuvant Treatment for Renal Cell Carcinoma: Do We Finally Have a Major Breakthrough? Clinical Advances in Hematology Oncology, 14 (11), 907-914.

Jani, C., Abdallah, N., Mouchati, C., Jani, R., Sharma, R., Bhatt, P. et al. (2022). Trends of kidney cancer burden from 1990 to 2019 in European Union 15 + countries and World Health Organization regions. Sci Rep, 12 (1), 22368. doi:10.1038/s41598-022-25485-8.

Bukavina, L., Bensalah, K., Bray, F., Carlo, M., Challacombe, B., Karam, J. A. et al. (2022). Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur. Urol, 82 (5), 529-542. doi: 10.1016/j.eururo.2022.08.019.

Makino, T., Kadomoto, S., Izumi, K., Mizokami, A. (2022). Epidemiology and Prevention of Renal Cell Carcinoma. Cancers, 14 (16), 4059. doi: 10.3390/cancers14164059.

Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J. et al. (2019). Epidemiology of Renal Cell Carcinoma. Eur. Urol, 75 (1), 74-84. doi: 10.1016/j.eururo.2018.08.036.

Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A., Bray, F. (2015). International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol, 67 (3), 519-530. doi: 10.1016/j.eururo.2014.10.002.

Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. Lyon, France. 2024. Available at: https://gco.iarc.who.int/today.

Chow, W. H., Dong, L. M., Devesa, S. S. (2010). Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol, 7 (4), 245-257. doi: 10.1038/nrurol.2010.46.

Ljungberg, B., Campbell, S. C., Choi, H. Y., Jacqmin, D., Lee, J. E., Weikert, S. et al. (2011). The epidemiology of renal cell carcinoma. Eur. Urol, 60 (4), 615-621. doi: 10.1016/j.eururo.2011.06.049.

Siegel, R. L., Miller, K. D., Jemal, A. (2017). Cancer Statistics, 2017. CA Cancer J. Clin, 67 (1), 7-30. doi: 10.3322/caac.21387.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M. et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 136 (5), E359-386. doi: 10.1002/ijc.29210.

National Comprehensive Cancer Network. Kidney cancer: NCCN guidelines for patients, version 1.2015. 2016. Available at: https://www2.tri-kobe.org/nccn/guideline/archive/urological2016-2017/english/kidney.pdf.

Siegel, R. L., Miller, K. D., Jemal, A. (2016). Cancer statistics, 2016. CA Cancer J. Clin, 66 (1), 7-30. doi: 10.3322/caac.21332.

Siegel, R., Ward, E., Brawley, O., Jemal, A. (2011). Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin, 61 (4), 212-236. doi: 10.3322/caac.20121.

Chow, W. H., Devesa, S. S. (2008). Contemporary epidemiology of renal cell cancer. Cancer J., 14 (5), 288-301. doi: 10.1097/PPO.0b013e3181867628.

Rampersaud, E. N., Klatte, T., Bass, G., Patard, J.-J., Bensaleh, K., Böhm, M. et al. (2014). The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol. Oncol, 32 (1), e9-13. doi: 10.1016/j.urolonc.2012.10.012.

Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H. et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J. Cancer, 49 (6), 1374-1403. doi: 10.1016/j.ejca.2012.12.027.

Cancer Over Time. WHO, IARC, Lyon, 2024. Available at: https://gco.iarc.fr.

Global Burden of Disease (GBD) study – 2021. Institute for Health Metrics and Evaluation (IHME). Available at: https://vizhub.healthdata.org/gbd-results/.

Siemer, S., Hack, M., Lehmann, J., Becker, F., Stöckle, M. (2006). Outcome of renal tumors in young adults. J. Urol, 175 (4), 1243-1244. doi: 10.1016/S0022-5347(05)00696-8.

Thompson, R. H., Ordonez, M. A., Iasonos, A., Secin, F. P., Guillonneau, B., Russo, P., Touijer, K. (2008). Renal cell carcinoma in young and old patients--is there a difference? J. Urol, 180 (4), 1262-1266. doi: 10.1016/j.juro.2008.06.037.

Cook, A., Lorenzo, A. J., Pippi Salle, J. L., Bakhshi, M., Cartwright, L. M., Bagi, D. et al. (2006). Pediatric renal cell carcinoma: single institution 25-year case series and initial experience with partial nephrectomy. J. Urol, 175 (4), 1456-1460. doi: 10.1016/S0022-5347(05)00671-3.

Siegel, R., Naishadham, D., Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J. Clin, 62 (1), 10-29. doi: 10.3322/caac.20138.

Berndt, S. I., Ballentine Carter, H., Schoenberg, M. P., Newschaffer, C. J. (2007). Disparities in treatment and outcome for renal cell cancer among older black and white patients. J. J. Clin. Oncol, 25 (24), 3589-3595. doi: 10.1200/JCO.2006.10.0156.

Rak v Ukraini, 2021-2022. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten natsionalnoho kantser-reiestru Ukrainy. 2022. № 24. Available at: http://www.ncru.inf.ua/publications/BULL_24/index.htm.

Rak v Ukraini, 2020-2021. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten natsionalnoho kantser-reiestru Ukrainy. 2021. No. 23. Available at: http://www.ncru.inf.ua/publications/BULL_23/index.htm.

Rak v Ukraini, 2019-2020. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten natsionalnoho kantser-reiestru Ukrainy. 2020. No. 22. Available at: http://www.ncru.inf.ua/publications/BULL_22/index.htm.

Downloads

Published

2024-12-05

Issue

Vol. 10 No. 3 (2024)

Section

Organizational and socio-economic bases of pharmaceutical activities

License

Copyright (c) 2024 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).